☎️ A frame for residents calling the on call attending:☎️ #TipsForNewDocs “I have a patient with ____ who I think needs ____”… …and then comes the story. 👊 PUNCHLINE FIRST 👊 Why? This changes how the recipient listens, and the old med school model of unfolding a

🚨Stockholm3 in a multiethnic cohort🚨 📄Journal of Clinical Oncology Compared with PSA, Stockholm3 test can 📉 unnecessary biopsies Finally, great data on a #prostatecancer biomarker from a diverse cohort (n~2k): Asian: 16% Black : 24 % Hispanic: 14% 👏 Hari Vigneswaran, MD Dr. Adam Murphy

Randomized Trial of Transverse vs Vertical Extraction Site Incision After Robotic Radical Prostatectomy | Journal of Urology auajournals.org/doi/10.1097/JU…

Oren Gottfried, MD A better one is this antibiotic circle from northwestern. We used it all the time during intern year.

AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or observation for 1 year. The pembrolizumab group had a median disease-free survival twice as long as the observation group. nej.md/4gh1b9D #ESMO24

Neoadjuvant chemotherapy plus durvalumab, followed by adjuvant durvalumab after cystectomy, led to event-free survival superior to that with neoadjuvant chemotherapy followed by cystectomy alone. Full NIAGARA trial results: nej.md/4gmAqk3 #ESMO24

Final results of National Cancer Institute RCT of Transperineal vs Transrectal Prostate Biopsy jamanetwork.com/journals/jamao…

How does Sunniforcast data fit into the non-clear cell landscape? Figure below may help (with shortcomings)?? Larger circles =⬆️ numbers, ringed circles = papillary only subsets. Are VEGF/PD1 doublets the standard of care. Nashville #UromigosLive live session this Saturday 28th!

A pleasure to finally share our findings of a large RCT of radical cystectomy patients from 10 Canadian institutions. To our shock, TXA did not reduce transfusion. Thank you to the patients, collaborators, and the many research staff. Wes Kassouf Dan McIsaac CIHR

More data showing Gem/Doce efficacy seems agnostic to traditional pathologic risk factors (ie multifocal HGT1 + CIS) Patients w EAU very high risk NMIBC had better outcomes w Gem/Doce in the paper below. Will be great to see what BRIDGE ultimately shows authors.elsevier.com/c/1k9jr3r93nct…

Fix it, don’t manage it. Vesicourethral anastomotic leak after RARP is devastating for the patient+surgeon. Sometimes a traumatic foley makes it worse like in this pt who’s 5 wks postop. Do you need to manage conservatively as traditional dogma states or can you just fix it?

Without looking it up: a "month" in a clinical trial is... (if not specified in the protocol)

Everyone talks about the importance of "validating" patient-reported outcome measures. But such validation studies are a very low bar ascopubs.org/doi/10.1200/JC…

NIH has announced a cut in the "indirect rate" to 15% across the board, in a move that appears to be retroactive to even existing grants. This is a bloodbath for research institutions throughout the country. Brief explainer for those not in this world: buff.ly/3EtML7D

TROPICS4 sacituzimab govitecan vs chemo in pretreated UC Annals of Oncology OS & PFS HRs=0.86. RR 23 vs 14, but G3+ TRAE 67 vs 35% with ⬆️ G5 TRD. While there is activity the ⬆️ tox & lower RR compared to EV/erda was problematic. Phase 2 Data on 2 other TROP2/TOPO1 ADCs #ASCOGU25

Resultados finales del COSMIC-313: Cabo+nivo+ipi vs Placebo+nivo+ipi 🔴PFS HR 0.82 (16.6 vs 11.2) 🔵OS HR 1.02 (41.9 vs 42) 🟡ORR 55.7% vs 25.4%

Enjoyed reading this from Sia Daneshmand, M.D. and team.Highlighted section - LOL! #testicularcancer

I don't know where I stand on all of the nuances of AI and copyright, but letting the AI **sign Frank Netter's name** at the bottom of its work seems like a bug that someone is going to be scrambling to fix shortly.